JMKX003948 / Shanghai Jeyou Pharmaceutical - LARVOL DELTA

A first-in-human phase 1 dose-escalation study of the oral HIF-2α inhibitor JMKX003948 in patients with renal cell carcinoma. (ASCO 2026) - P1 | "JMKX003948 is well tolerated and shows promising antitumor activity in patients with advanced ccRCC."

Clinical • First-in-human • P1 data • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Hematological Disorders • Oncology • Renal Cell Carcinoma • Renal Disease • Solid Tumor • EPAS1

Study of JMKX003948 Ophthalmic Suspension in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Jemincare

New P1 trial • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders

A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Jemincare | Not yet recruiting ➔ Recruiting

Enrollment open • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Jemincare

New P1 trial • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs (BioSpace) - "On November 28, NMPA has approved a clinical trial for JMKX003948 to treat renal cell carcinoma....On December 12, FDA has approved a clinical trial for JMKX000197 to treat BCG-unresponsive non-muscle-invasive bladder cancer, and earlier on October 19, NMPA has approved the clinical trial."

IND • New trial • Bladder Cancer • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor